Search

Displaying results 3241 - 3250 of 10000 in total
  1. Drug

    PX-478

    go.drugbank.com/drugs/DB06082
    Investigational

    PX-478 was effective in models of both non-small cell lung cancer and small cell lung cancer that express HIF-1 alpha. … PX-478 is a small molecule inhibitor of hypoxia inducible factor (HIF)-1 alpha currently in a clinical trial in patients with advanced metastatic cancer and lymphoma.

  2. Drug

    Streptococcus pneumoniae type 33f capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10341
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 33f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 33f of *Streptococcus pneumoniae

    Mixtures: PNEUMOVAX 23 Injektionslösung in einer Fertigspritze, PNEUMOVAX 23 Injektionslösung in einer Durchstechflasche
  3. Drug

    Streptococcus pneumoniae type 17f capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10334
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 17f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 17f of *Streptococcus pneumoniae

    Mixtures: PNEUMOVAX 23 Injektionslösung in einer Fertigspritze, PNEUMOVAX 23 Injektionslösung in einer Durchstechflasche
  4. Drug

    Denufosol

    go.drugbank.com/drugs/DB04983
    Investigational

    Denufosol was an inhaled drug used for the treatment of cystic fibrosis (CF), showing various improvements in lung function during a phase III clinical trial. … A new drug application (NDA) was filed with the FDA in 2011, however, the second phase III clinical trial showed a lack of improvement in lung function for cystic fibrosis patients taking denufosol.

  5. Drug

    Vortioxetine

    go.drugbank.com/drugs/DB09068
    ApprovedInvestigational

    Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). … Some serotonin receptors seem to play a relatively neutral or insignificant role in the regulation of mood, but others, such as 5-HT1A autoreceptors and 5-HT7 receptors, appear to play an oppositional

    Categories: Antidepressive Agents Indicated for Depression, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  6. Drug

    Asenapine

    go.drugbank.com/drugs/DB06216
    ApprovedInvestigational

    Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009. … Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  7. Drug

    Thymalfasin

    go.drugbank.com/drugs/DB04900
    Investigational

    Thymosin alpha 1 is now approved in 35 developing countries for the treatment of Hepatitis B and C. It is also used to boost the immune response in the treatment of other diseases. … Thymalfasin is a chemically synthesized version of thymosin alpha 1 that is identical to human thymosin alpha 1. Thymosin alpha 1 is an acetylated polypeptide.

  8. Drug

    Moxetumomab pasudotox

    go.drugbank.com/drugs/DB12688
    ApprovedInvestigational

    [A38864] MxP appears as an improved form of BL22 by the mutation of the Fv region and the antibody phage-displayed. As well the residues SSY in the heavy chain are mutated to THW. … This antibody was used to generate a recombinant immunotoxin in which a stabilized Fv segment by a disulfide bond is fused to the _Pseudomonas_ exotoxin A (PE38) which does not have the cell-binding portion

  9. Drug

    Droxidopa

    go.drugbank.com/drugs/DB06262
    ApprovedInvestigational

    Chelsea Therapeutics obtained orphan drug status (ODS) for L-DOPS in the U.S. for NOH, and that of which associated with Parkinson's disease , pure autonomic failure, and multiple system atrophy, and is … Provided L-DOPS successfully completes clinical trials, it could be approved for the treatment of neurogenic orthostatic hypotension (NOH) as early as 2011.

  10. Drug

    Streptococcus pneumoniae type 12f capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10331
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 12f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 12f of *Streptococcus pneumoniae

    Mixtures: PNEUMOVAX 23 Injektionslösung in einer Fertigspritze, PNEUMOVAX 23 Injektionslösung in einer Durchstechflasche